Article Text

other Versions

PDF
Measuring decline in prodromal AD: a pike to hike
  1. José Luis Molinuevo
  1. Correspondence to Dr José Luis Molinuevo, Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain; jlmoli{at}clinic.ub.es

Statistics from Altmetric.com

A rational explanation for selecting neuropsychological tests for the cognitive follow-up of patients with prodromal AD

A few years ago, the International Working Group (IWG) new research criteria created the framework to establish a specific diagnosis in the predementia or prodromal stage of Alzheimer's disease (AD).1 This was the first step to introduce biomarkers as part of the diagnosis of AD and to move forward the diagnosis to earlier stages, clarifying therefore the underlying aetiology of mild cognitive impairment. The diagnosis in the prodromal stage, applying the IWG criteria, has been already applied in research settings and incorporated as part of inclusion criteria of several clinical trials; by contrast, there is yet no clear conviction that the time of AD diagnosis can be reliably advanced to the prodromal stage in clinical …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles